To evaluate the concordance between the EEG diagnosis of non-convulsive status epilepticus (NCSE) made by the treating physician and the application of the Salzburg Consensus Criteria (SCC) on consecutive urgent EEG requested for acute alteration of consciousness not otherwise explained. Methods: Retrospective evaluation of all urgent EEGs acquired between January 1st and March 31st 2018 in adolescents and adult patients (≥14 years old). The 'reference' was the neurologist who first evaluated the patient and reported the corresponding EEG diagnosis. All were blind to the SCC. All included EEG were evaluated and classified by three neurologists trained in the application of SCC blind to the clinical diagnosis. Results: 181 consecutive EEGs entered the study. The treating clinician diagnosed a NCSE in 17 cases (9%). According to the SCC, 12 EEGs were classified as Definite NCSE (7%), 71 (39 %) as Possible NCSE, and 98 (54 %) as no NCSE. A perfect concordance was found for the Definite-and No-NCSE categories, while only 5 patients with a Possible-NCSE were diagnosed by the treating clinician as having NCSE. It is relevant to note that aamong the 66 patients with a Possible NCSE not diagnosed as SE by the treating clinician, only two presented an evolution toward a definite SE. Conclusion: SCC have optimal performances for the 'Definite NCSE', and to exclude the presence of a NCSE. Conversely, the Possible NCSE category is still a a grey land of debate that could potentially include many different conditions. Recently, however, a Netherlands group [13] made an external

No abstract

The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.

Objective To study Ramadan's effect on migraine from the start to the end of the month and the tolerability of patients with migraine to fasting. Background Fasting is a well‐known trigger for migraine. Whether this effect on migraine is the same throughout the whole month, or whether it varies from the first to the last days of the month, has not been studied yet. Methods A prospective cohort observational study was carried out on persons with migraine who fasted from 24 April to 23 May during Ramadan 2020. Each patient was asked to fill out their headache diary starting from Shaaban (the month before Ramadan) to the end of Ramadan. The Ramadan diary was divided by 10 days each, by which the patient was asked to accurately describe their migraine attacks in terms of frequency, duration, and intensity by using the Visual Analog Scale. Migraine attacks during the first day of fasting were assessed separately. Results A total of 292 known persons with migraine from Egypt completed the study. Their median age was 33 years; 72/292 (24.7%) were male, and 220/292 (75.3%) were female. About 126/236 (53.4%) of the patients had migraine attacks on Ramadan's first day, most of them during fasting. The frequency of migraine attacks was significantly increased in Ramadan (median 4, interquartile range [IQR] 2–7) compared with Shaaban (median 3, IQR 1–6), p = 0.009. The number of attacks was significantly reduced in both the second (median 1, IQR 0–2.25) and the third 10 days of Ramadan (median 1, IQR 1–3) compared with the first 10 days (median 3, IQR 1–5) (p < 0.001 for each). Conclusion Ramadan's potential exacerbating effect on the frequency of migraine attacks should be discussed with patients with migraine. This effect appears to be limited to the first 10 days of Ramadan and then subsides with successive days of fasting.